HDAC9 and mantle cell lymphoma: On the other hand, the combination of proteasome and HDAC inhibitors has been shown to interact strongly to promote apoptosis in cancer cell lines [14–16], and this combination therapy has been tested in clinical trials for mantle cell lymphomas [6].